Hyderabad: The world’s first intranasal heterologous booster dose has begun to be dispatched by Bharat Biotech to hospitals, Executive Chairman Dr. Krishna Ella announced on February 5. The dispatch started two days back, informed Ella. India can innovate for both the country and the rest of the world, as evidenced by this vaccination, Dr. Krishna Ella earlier said.
He discussed the delivery of vaccines under the bilateral agreement between the Ella Foundation and the UW-Madison Global Health Institute for the establishment of the first-ever UW-Madison One Health Center in India for improving vaccines, medicines and global health education.
The initial two-dose schedule and a heterologous booster dose, both given as nasal drops, have been approved for the first time for an intranasal COVID vaccination, known as iNCOVACC. The vaccination eliminates the need for syringes, needles, alcohol wipes, and bandages, which reduces the cost of production, distribution, storage, and disposal of biomedical waste.
Adenovirus vaccine with a pre-fusion stabilised spike protein called iNCOVACC is a recombinant replication-deficient vaccine. Phase I, II, and III clinical trials on this vaccine candidate had positive outcomes.
On the occasion of Republic DayHyderabad:, Mansukh Mandaviya, the Union Health Minister, and Jitendra Singh, the Union Minister of Science and Technology, launched iNCOVACC.
For large-scale purchases by the Central and state governments, the vaccine is priced at ₹325 per dosage. The intranasal vaccine is painless to administer and stable at 2 to 8°C for convenient storage and distribution.
